hit counter
Allergan plc (AGN) Stock News Sentiment & Price - Sentifly
AGN - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Allergan plc (AGN)

USA
Drugs - Generic
NYSE
AGN Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AGN Latest news
Business Wire
Neutral
Hagens Berman: Law Firm Investigating Permanent Injuries and Disfigurement from Botched CoolSculpting Procedures
2021-10-05 07:00

SEATTLE--(BUSINESS WIRE)---- $AGN #CoolSculpting--Attorneys at Hagens Berman are investigating CoolSculpting personal injury claims related to paradoxical adipose hyperplasia (PAH) after treatment.

Benzinga
Positive
Allergan Shares Updated Data From Vision Loss Candidate Showing Significant Improvement In Near-Vision Reading
2021-07-26 06:52

Allergan, a unit of AbbVie Inc (NYSE: ABBV), has announced new data, including the full results from the Phase 3 GEMINI 1 study of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for presbyopia. Multiple data presentations were made at the 2021 ASCRS Annual Meeting.

Proactive Investors
Negative
Firms fined £260mln for 10,000% rise in price of NHS hydrocortisone tablets
2021-07-15 03:31

A group of companies including Irish drug giant Allergan PLC (NYSE:AGN) and private equity group Cinven have been fined more than £260mln for rigging prices of hydrocortisone drugs sold to the NHS. UK competition regulator the CMA said that two companies in particular - Auden Mackenzie and Actavis UK (now called Accord-UK) - charged the NHS excessively high prices for almost a decade.

CNBC Television
Neutral
Former Allergan CEO says pausing J&J vaccine is an 'overreaction'
2021-04-13 16:55

Brent Saunders, former Allergan CEO, joins 'Closing Bell' to discuss the FDA and CDC's decision to pause the J&J vaccine after six women developed rare blood clots after they received the vaccine. The FDA and CDC is investigating whether the blood clots were caused by the J&J vaccine.

Newsfile Corp
Neutral
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Allergan plc and Encourages Investors with Losses to Contact the Firm
2021-04-13 16:28

Los Angeles, California--(Newsfile Corp. - April 13, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allergan plc ("Allergan" or "the Company") (NYSE: AGN) for violations of the securities laws.The investigation focuses on whether Allergan issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to participate.We also...

Newsfile Corp
Neutral
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Allergan plc and Encourages Investors with Losses to Contact the Firm
2021-04-02 18:51

Los Angeles, California--(Newsfile Corp. - April 2, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allergan plc ("Allergan" or "the Company") (NYSE: AGN) for violations of the securities laws.The investigation focuses on whether Allergan issued false and/or misleading statements and/or failed to disclose information pertinent to investors.If you are a shareholder who suffered a loss, click here to participate.We also...

Benzinga
Neutral
AbbVie's Allergan Files US Application AGN-190584 For Presbyopia
2021-02-25 13:43

Allergan, an AbbVie Inc (NYSE: ABBV), has submitted a marketing application to the FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia. The FDA is expected to act on the application by the end of 2021.

GlobeNewsWire
Neutral
Worldwide Facial Injectable Industry to 2025 - by Type, Generation, End-user and Geography
2021-02-24 05:13

Dublin, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The "Facial Injectable Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering. The facial injectable market is projected to grow at a CAGR of 14.22% to reach US$21.727 billion by 2025 from US$9.780 billion in 2019. Products pertaining to facial injectables which are also referred to as dermal fillers that are intended to reconstruct, bioengineer facial features as well for facial rejuvenation to rectify wrinkles caused due to the loss of subcutaneous fat over the face that is experienced by individuals as they grow old. The products are necessary for treating early signs of aging or complement facial rejuvenation surgery. Additionally, the growing consciousness about appearance along with the increasing pool of geriatric population is the primary driver that is estimated to catapult the facial injectable market to new heights during the forecast period. Moreover, the increasing shift towards minimally invasive procedures and c

Benzinga
Positive
Allergan's BOTOX Wins FDA Nod For Neurologic Condition-Associated Pediatric Detrusor Overactivity
2021-02-10 11:05

The FDA has approved Allergan and AbbVie Inc's (NYSE: ABBV) BOTOX (onabotulinumtoxinA). It is used to treat detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients five years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.

Newsfile Corp
Neutral
FINAL DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Allergan plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2020-10-29 16:09

Los Angeles, California--(Newsfile Corp. - October 29, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Allergan plc ("Allergan" or "the Company") (NYSE: AGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 9, 2017 and December 19, 2018, inclusive...

Loading more news...